Mariana Machado Matos, Renan Arthur Bosio-Guimarães, Ana Júlia Schmidt Niederauer, Katia Isabel Fercondini Pastre, Ronilson A Moreno, Simone Grigoletto Schramm, Paulo Alexandre Rebelo Galvinas, Gustavo D Mendes, Gilberto De Nucci
Capecitabine is a prodrug and is selectively activated by tumor cells to its cytotoxic moiety, 5-fluorouracil, by thymidine phosphorylase, which is generally expressed at high levels in tumors. Clinical and pharmacokinetic studies of capecitabine have been performed in patients with cancer. This study aims to evaluate the bioequivalence of two capecitabine formulations (150-mg tablet) using healthy male subjects under nonfasting conditions. The study was conducted as an open, randomized, three-period, semi-replicated design with three sequences (RRT, RTR, TRR) with a 1-week washout interval...
October 2018: International Journal of Clinical Pharmacology and Therapeutics